en.Wedoany.com Reported - Curium, a global leader in nuclear medicine, announced at the "Choose France" summit held in Versailles an investment of €32 million in France to build a new production line and create 20 highly skilled jobs, thereby enhancing its radiopharmaceutical manufacturing capacity. This production line will supply the European market with ¹⁷⁷Lu-PSMA-I&T, a targeted radioligand therapy (RLT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
Through this investment, Curium is positioning itself as a theranostic company, combining its long-standing expertise in diagnostics with a therapeutic portfolio built around RLT. In France, Curium employs over 750 people, operates 13 production sites, and serves more than 200 nuclear medicine centers daily. The investment is located in Saclay, Curium's historical birthplace, which boasts a world-class research ecosystem deeply rooted in the legacy of the French Alternative Energies and Atomic Energy Commission (CEA). Having invested over €50 million in France over the past five years, this new investment aims to scale up its diagnostic and therapeutic product lines to meet a market demand projected to grow tenfold by 2035.
Curium International CEO Cyrille Faya stated that France is a key production hub for Curium, accounting for over 20% of global revenue, and that nuclear medicine, particularly radioligand therapy, will become a vital component of modern cancer treatment. Isabelle Ruzu, Senior Vice President and Head of Quality and Operations at Curium International, noted that France was chosen for its high-quality scientific, industrial, and healthcare ecosystem. This investment will create new opportunities for highly skilled talent and help improve cancer patients' access to radioligand therapy.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
